Mirum Pharmaceuticals, Inc.·4

Apr 16, 8:40 PM ET

Ramasastry Saira 4

4 · Mirum Pharmaceuticals, Inc. · Filed Apr 16, 2026

Research Summary

AI-generated summary of this filing

Updated

Mirum (MIRM) Director Saira Ramasastry Exercises Options, Sells Shares

What Happened

  • Director Saira Ramasastry exercised stock options and sold shares on April 15, 2026. She exercised 2,000 optioned shares at $23.51 ($47,020 cost) and immediately sold 2,000 shares in the open market at $96.90 for $193,800 in proceeds. The filing also reports a separate derivative conversion of 2,000 shares recorded as disposed at $0.00 (the filing does not explain that entry).
  • This sequence (exercise followed by an immediate sale) is effectively an option exercise with a prompt sale of the underlying shares (a common way to realize gains).

Key Details

  • Transaction dates: April 15, 2026; Form 4 filed April 16, 2026 (covers 4/15/26).
  • Exercise: 2,000 shares at $23.51 = $47,020 (coded M, acquired).
  • Sale: 2,000 shares at $96.90 = $193,800 (coded S, disposed).
  • Additional derivative entry: 2,000 shares at $0.00 (coded M, disposed); no explanation in the reported excerpt.
  • Footnotes: Transaction occurred under a Rule 10b5-1 trading plan adopted Sept 18, 2025 (F1). The stock option exercised was fully vested (F2).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Timeliness: Filing was submitted the day after the transaction (appearance of timely reporting).

Context

  • For retail investors: exercises followed by immediate sales are routine ways insiders convert option gains to cash and do not necessarily signal a change in company outlook. The presence of a 10b5-1 plan indicates the sale was pre-planned under an established trading arrangement.

Insider Transaction Report

Form 4
Period: 2026-04-15
Transactions
  • Exercise/Conversion

    Common Stock

    2026-04-15$23.51/sh+2,000$47,0202,000 total
  • Sale

    Common Stock

    [F1]
    2026-04-15$96.90/sh2,000$193,8000 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F2]
    2026-04-152,0002,000 total
    Exercise: $23.51Exp: 2032-06-01Common Stock (2,000 underlying)
Footnotes (2)
  • [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025.
  • [F2]The stock option is fully vested.
Signature
/s/ Judit Ryvkin, Attorney-in-Fact|2026-04-16

Documents

1 file
  • 4
    form4-04172026_120419.xmlPrimary